Serotonin levels and 1-year mortality in patients with neuroendocrine tumors: A systematic review and meta-analysis

Vijay N. Joish; Sandip Shah; Jonothan C. Tierce; Deep Patel; Chad McKee; Pablo Lapuerta; Jerome Zacks

doi:10.2217/fon-2018-0960

Serotonin levels and 1-year mortality in patients with neuroendocrine tumors: A systematic review and meta-analysis

Vijay N. Joish
, Sandip Shah
, Jonothan C. Tierce
, Deep Patel
, Chad McKee
, Pablo Lapuerta
, Jerome Zacks

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Abstract

Aim: Elevated serotonin in patients with neuroendocrine tumors (NETs) may impact heart failure incidence but a quantitative relationship has not been established. Materials & methods: Systematic review and meta-analysis of studies assessing 24-h urinary 5-hydroxyindoleacetic acid (u5-HIAA) and mortality in patients with NETs (2007-2017) with a primary outcome of 1-year mortality risk and 24-h u5-HIAA. Results: We identified 1715 records of which 12 studies including 755 patients (3442 person-years with 376 deaths) were eligible for meta-analysis. Mean u5-HIAA was 149.2 mg/24 h (standard deviation: 96.6) and mortality was 13.0%. The meta-regression equation showed an 11.8% (95% CI: 8.9-17.0%; I ² = 93.0%) increase in 1-year mortality for every ten-unit increase in u5-HIAA. Conclusion: Serotonin measured by its metabolite u5-HIAA is predictive of 1-year all-cause mortality in patients with NETs.

Original language	English
Pages (from-to)	1397-1406
Number of pages	10
Journal	Future Oncology
Volume	15
Issue number	12
DOIs	https://doi.org/10.2217/fon-2018-0960
State	Published - Apr 2019
Externally published	Yes

Keywords

carcinoid syndrome
mortality
neuroendocrine tumors
serotonin

Access to Document

10.2217/fon-2018-0960

Cite this

@article{4a8b03cdc7e34f628b98b088c730db59,

title = "Serotonin levels and 1-year mortality in patients with neuroendocrine tumors: A systematic review and meta-analysis",

abstract = " Aim: Elevated serotonin in patients with neuroendocrine tumors (NETs) may impact heart failure incidence but a quantitative relationship has not been established. Materials \& methods: Systematic review and meta-analysis of studies assessing 24-h urinary 5-hydroxyindoleacetic acid (u5-HIAA) and mortality in patients with NETs (2007-2017) with a primary outcome of 1-year mortality risk and 24-h u5-HIAA. Results: We identified 1715 records of which 12 studies including 755 patients (3442 person-years with 376 deaths) were eligible for meta-analysis. Mean u5-HIAA was 149.2 mg/24 h (standard deviation: 96.6) and mortality was 13.0\%. The meta-regression equation showed an 11.8\% (95\% CI: 8.9-17.0\%; I 2 = 93.0\%) increase in 1-year mortality for every ten-unit increase in u5-HIAA. Conclusion: Serotonin measured by its metabolite u5-HIAA is predictive of 1-year all-cause mortality in patients with NETs.",

keywords = "carcinoid syndrome, mortality, neuroendocrine tumors, serotonin",

author = "Joish, \{Vijay N.\} and Sandip Shah and Tierce, \{Jonothan C.\} and Deep Patel and Chad McKee and Pablo Lapuerta and Jerome Zacks",

note = "Publisher Copyright: {\textcopyright} 2019 2019 Vijay N Joish.",

year = "2019",

month = apr,

doi = "10.2217/fon-2018-0960",

language = "English",

volume = "15",

pages = "1397--1406",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Taylor and Francis Ltd.",

number = "12",

}

TY - JOUR

T1 - Serotonin levels and 1-year mortality in patients with neuroendocrine tumors

T2 - A systematic review and meta-analysis

AU - Joish, Vijay N.

AU - Shah, Sandip

AU - Tierce, Jonothan C.

AU - Patel, Deep

AU - McKee, Chad

AU - Lapuerta, Pablo

AU - Zacks, Jerome

PY - 2019/4

Y1 - 2019/4

N2 - Aim: Elevated serotonin in patients with neuroendocrine tumors (NETs) may impact heart failure incidence but a quantitative relationship has not been established. Materials & methods: Systematic review and meta-analysis of studies assessing 24-h urinary 5-hydroxyindoleacetic acid (u5-HIAA) and mortality in patients with NETs (2007-2017) with a primary outcome of 1-year mortality risk and 24-h u5-HIAA. Results: We identified 1715 records of which 12 studies including 755 patients (3442 person-years with 376 deaths) were eligible for meta-analysis. Mean u5-HIAA was 149.2 mg/24 h (standard deviation: 96.6) and mortality was 13.0%. The meta-regression equation showed an 11.8% (95% CI: 8.9-17.0%; I 2 = 93.0%) increase in 1-year mortality for every ten-unit increase in u5-HIAA. Conclusion: Serotonin measured by its metabolite u5-HIAA is predictive of 1-year all-cause mortality in patients with NETs.

AB - Aim: Elevated serotonin in patients with neuroendocrine tumors (NETs) may impact heart failure incidence but a quantitative relationship has not been established. Materials & methods: Systematic review and meta-analysis of studies assessing 24-h urinary 5-hydroxyindoleacetic acid (u5-HIAA) and mortality in patients with NETs (2007-2017) with a primary outcome of 1-year mortality risk and 24-h u5-HIAA. Results: We identified 1715 records of which 12 studies including 755 patients (3442 person-years with 376 deaths) were eligible for meta-analysis. Mean u5-HIAA was 149.2 mg/24 h (standard deviation: 96.6) and mortality was 13.0%. The meta-regression equation showed an 11.8% (95% CI: 8.9-17.0%; I 2 = 93.0%) increase in 1-year mortality for every ten-unit increase in u5-HIAA. Conclusion: Serotonin measured by its metabolite u5-HIAA is predictive of 1-year all-cause mortality in patients with NETs.

KW - carcinoid syndrome

KW - mortality

KW - neuroendocrine tumors

KW - serotonin

UR - https://www.scopus.com/pages/publications/85065096418

U2 - 10.2217/fon-2018-0960

DO - 10.2217/fon-2018-0960

M3 - Review article

C2 - 30734573

AN - SCOPUS:85065096418

SN - 1479-6694

VL - 15

SP - 1397

EP - 1406

JO - Future Oncology

JF - Future Oncology

IS - 12

ER -

Serotonin levels and 1-year mortality in patients with neuroendocrine tumors: A systematic review and meta-analysis

Abstract

Keywords

Access to Document

Fingerprint

Cite this